Pluri (PLUR) Competitors $4.34 +0.02 (+0.56%) As of 03:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PLUR vs. CLLS, ATRA, PEPG, PYXS, ALXO, PWUP, ADVM, IMAB, ENTX, and GNTAShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Cellectis (CLLS), Atara Biotherapeutics (ATRA), PepGen (PEPG), Pyxis Oncology (PYXS), ALX Oncology (ALXO), PowerUp Acquisition (PWUP), Adverum Biotechnologies (ADVM), I-Mab (IMAB), Entera Bio (ENTX), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Cellectis Atara Biotherapeutics PepGen Pyxis Oncology ALX Oncology PowerUp Acquisition Adverum Biotechnologies I-Mab Entera Bio Genenta Science Cellectis (NASDAQ:CLLS) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk, community ranking and valuation. Which has more risk and volatility, CLLS or PLUR? Cellectis has a beta of 3.08, suggesting that its stock price is 208% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Does the MarketBeat Community believe in CLLS or PLUR? Cellectis received 407 more outperform votes than Pluri when rated by MarketBeat users. CompanyUnderperformOutperformCellectisOutperform Votes40764.91% Underperform Votes22035.09% PluriN/AN/A Does the media favor CLLS or PLUR? In the previous week, Cellectis had 5 more articles in the media than Pluri. MarketBeat recorded 6 mentions for Cellectis and 1 mentions for Pluri. Cellectis' average media sentiment score of 0.22 beat Pluri's score of 0.00 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pluri 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of CLLS or PLUR? 63.9% of Cellectis shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 10.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend CLLS or PLUR? Cellectis currently has a consensus price target of $7.00, suggesting a potential upside of 372.97%. Given Cellectis' stronger consensus rating and higher probable upside, research analysts plainly believe Cellectis is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Pluri 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings and valuation, CLLS or PLUR? Pluri has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectis$9.19M8.95-$101.06M-$1.30-1.14Pluri$330K70.43-$20.89M-$6.03-0.69 Is CLLS or PLUR more profitable? Cellectis has a net margin of -234.39% compared to Pluri's net margin of -4,184.28%. Cellectis' return on equity of -74.55% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Cellectis-234.39% -74.55% -22.65% Pluri -4,184.28%-917.18%-82.85% SummaryCellectis beats Pluri on 14 of the 16 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.01M$2.96B$5.34B$9.11BDividend YieldN/A1.89%5.37%4.00%P/E Ratio-0.6916.4456.8413.06Price / Sales70.43288.031,275.3476.04Price / CashN/A189.5236.6132.89Price / Book4.183.924.874.58Net Income-$20.89M-$40.99M$118.05M$224.84M7 Day Performance-6.49%1.13%1.47%2.37%1 Month Performance-13.28%-1.72%2.54%4.40%1 Year Performance-9.16%-2.23%25.37%20.10% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri0.1413 of 5 stars$4.34+0.6%N/A-9.2%$24.15M$330,000.00-0.72150News CoverageCLLSCellectis3.2297 of 5 stars$1.68-9.2%$7.00+316.7%-45.0%$93.38M$29.07M-1.29290Gap UpATRAAtara Biotherapeutics4.0785 of 5 stars$16.19+4.1%$18.75+15.8%-58.6%$93.25M$100.44M-0.63330News CoverageGap DownPEPGPepGen3.0784 of 5 stars$2.80-5.7%$13.67+388.1%-65.8%$91.27MN/A-0.9430PYXSPyxis Oncology1.4954 of 5 stars$1.53-1.3%$9.43+516.2%-35.6%$90.98M$16.15M-1.4960Positive NewsALXOALX Oncology3.8838 of 5 stars$1.69-4.5%$8.50+403.0%-86.9%$89.14MN/A-0.5740Positive NewsGap UpPWUPPowerUp AcquisitionN/A$11.43flatN/A+4.7%$88.75MN/A0.00N/APositive NewsADVMAdverum Biotechnologies3.6577 of 5 stars$4.20-1.6%$27.83+562.7%-48.9%$87.37M$1M-0.70190IMABI-Mab2.7303 of 5 stars$1.07+1.9%$8.00+647.7%-30.5%$87.21M$3.27M0.00380Gap UpENTXEntera Bio3.0898 of 5 stars$2.40-2.0%$10.00+316.7%+134.0%$85.88M$99,000.00-9.2320Positive NewsGNTAGenenta Science2.9592 of 5 stars$4.65-2.1%$25.00+437.6%-11.7%$85.05MN/A0.007 Related Companies and Tools Related Companies Cellectis Competitors Atara Biotherapeutics Competitors PepGen Competitors Pyxis Oncology Competitors ALX Oncology Competitors PowerUp Acquisition Competitors Adverum Biotechnologies Competitors I-Mab Competitors Entera Bio Competitors Genenta Science Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PLUR) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
